EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
The paper analyzes the data available in the literature on the mechanisms of action of certolizumab pegol (CZP), a new tumor necrosis factor-α (TNF-α) inhibitor for the treatment of active psoriatic arthritis (PsA). It describes the unique molecular structure of the drug and its mechanism of action...
Saved in:
| Main Authors: | T. V. Korotaeva, E. Yu. Loginova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2015-10-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Certolizumab pegol in therapy for rheumatoid arthritis
by: Galina Viktorovna Lukina, et al.
Published: (2012-06-01) -
Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01) -
CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
by: P. I. Novikov, et al.
Published: (2018-07-01) -
New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
by: Dmitry Evgenyevich Karateev, et al.
Published: (2012-04-01) -
A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
by: Meng Liu, et al.
Published: (2025-08-01)